Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

3.0%

1 terminated out of 33 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

55%

6 of 11 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (7)
Early P 1 (3)
P 1 (6)
P 2 (9)
P 3 (1)
P 4 (1)

Trial Status

Recruiting11
Completed11
Withdrawn3
Active Not Recruiting3
Unknown2
Terminated1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT05621668Phase 1Recruiting

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

NCT03442465RecruitingPrimary

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

NCT05051059Not ApplicableRecruiting

Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients

NCT05033288RecruitingPrimary

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

NCT04698785Phase 2RecruitingPrimary

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

NCT04055220Not ApplicableRecruitingPrimary

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT06409013RecruitingPrimary

Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma

NCT05746429Not ApplicableCompletedPrimary

Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer

NCT04616248Phase 1Active Not Recruiting

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT02811523Phase 1RecruitingPrimary

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

NCT03449108Phase 2Active Not RecruitingPrimary

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03244020Phase 4Enrolling By Invitation

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT00592293Not ApplicableCompleted

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

NCT06129903Not ApplicableRecruiting

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

NCT04634227Early Phase 1Active Not Recruiting

Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

NCT04181970Recruiting

Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

NCT04963517Phase 2CompletedPrimary

Exercise Intervention for Bone Tumor Patients

NCT06669013Phase 3RecruitingPrimary

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

NCT03277924Phase 1Completed

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

NCT01803152Phase 1Completed

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Scroll to load more

Research Network

Activity Timeline